Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma
Clin Mol Hepatol
.
2024 Sep 2.
doi: 10.3350/cmh.2024.0682.
Online ahead of print.
Authors
Meng-Che Wu
1
2
3
,
Hui-Chin Chang
3
4
5
,
Yi-Sheng Jhang
6
,
Shuo-Yan Gau
7
8
9
Affiliations
1
Division of Pediatric Gastroenterology, Children's Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan.
2
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
3
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
4
Evidence-based Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan.
5
Library, Chung Shan Medical University Hospital, Taichung, Taiwan.
6
Department of Pharmacy, Chung Shan Medical University Hospital, Taichung, Taiwan.
7
Department and Graduate Institute of Business Administration, National Taiwan University, Taipei, Taiwan.
8
Department of Pharmacology, Chung Shan Medical University, Taichung, Taiwan.
9
Orthopedics Department, Chi-Mei Medical Center, Tainan, Taiwan.
PMID:
39219337
DOI:
10.3350/cmh.2024.0682
No abstract available
Keywords:
cohort study; epidemiology; hepatocellular carcinoma.